Evidence map›Paper›PMID 40957901›Full record

ArticleMolecular psychiatry2026

Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation.

Anqi Lin, Yiyin Mai, Guichuan Lai, Zhengrui Li, Junyi Shen, Hank Z H Wong, Nan Zhang, Jian Zhang, Kailai Li, Quan Cheng and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anqi Lin *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Yiyin Mai *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Guichuan Lai *Department of Health Statistics, School of Public Health, Chongqing Medical University, Chongqing, 401331, China.
Zhengrui Li *Department of Oral and Cranio-Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, 200011, China.
Junyi Shen *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Hank Z H WongLi Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Nan ZhangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Kailai LiDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Bicheng YeLiver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Nanjing, China.
Aimin JiangDepartment of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, 200433, China. czjiangaimin@smmu.edu.cn.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. luopeng@smu.edu.cn.ORCID http://orcid.org/0000-0002-8215-2045
Guiqing JiaDepartment of Gastrointestinal Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. jiaguiqing@med.uestc.edu.cn.
Qunqing ChenDepartment of Cardiothoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China. chenqqg1985@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taxane drugs are essential chemotherapeutic agents in the clinical management of various solid tumors; however, their associated psychiatric adverse effects and underlying mechanisms remain insufficiently explored. This study aims to assess the association between taxane drugs and psychiatric adverse events (pAEs) and to investigate their potential biological mechanisms. The association between taxane drugs and pAEs was analyzed using the reporting odds ratio (ROR) method based on data from the Food and Drug Administration Adverse Event Reporting System (FAERS) (2013-2023) and the World Health Organization's global pharmacovigilance database (Vigibase database). Tumor-bearing mouse models treated with taxane drugs were developed, and RNA sequencing was conducted to examine the underlying molecular mechanisms. Single-sample gene set enrichment analysis (ssGSEA) was performed to evaluate the activity of relevant pathways. A total of 10,132 cases and 10,525 cases of pAEs associated with taxane drugs were identified in the FAERS and Vigibase databases, respectively. Nine significant taxane-related psychiatric adverse events (TX-related pAEs) were identified, with emotional distress showing the strongest signal. Subgroup analysis indicated that women (ROR

Indexed as

Mental DisordersTaxoidsAdultAdverse Drug Reaction Reporting SystemsAgedAnimalsAntineoplastic AgentsBridged-Ring CompoundsDatabases, FactualDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMiceMiddle AgedPharmacovigilanceAntineoplastic AgentsBridged-Ring CompoundstaxaneTaxoids

Identifiers

PMID40957901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.